NEW ORLEANS, Louisiana, June 11, 2026
Gan & Lee Pharmaceuticals presented four significant research findings from its innovative metabolic disease pipeline at the 86th Scientific Sessions of the American Diabetes Association (ADA) 2026, highlighting continued progress across its next-generation diabetes and obesity treatment portfolio. The studies featured data on Bofanglutide (GZR18), a potentially first-in-class biweekly GLP-1 receptor agonist, Insulin Ludefen (GZR4), a once-weekly basal insulin candidate, and GZR102, a novel fixed-ratio combination therapy integrating basal insulin and GLP-1 receptor agonist technology. The research findings, published in Diabetes®, the official journal of the ADA, further strengthen the scientific foundation supporting the company’s late-stage clinical development programs. With both GZR18 and GZR4 currently advancing through Phase 3 clinical trials, Gan & Lee continues to position itself at the forefront of innovation in metabolic disease management, targeting improved efficacy, convenience, and long-term outcomes for patients living with diabetes and obesity.
Bofanglutide Demonstrates Strong Safety and Combination Potential
Among the highlights presented at ADA 2026 were two studies evaluating Bofanglutide (GZR18), a long-acting GLP-1 receptor agonist designed for administration every two weeks. One study examined the effects of renal impairment on the pharmacokinetics and safety of Bofanglutide, demonstrating that patients with mild, moderate, or severe renal impairment experienced drug exposure levels comparable to individuals with normal kidney function. The findings suggest that dose adjustments may not be required in patients with renal impairment, an important consideration for individuals with diabetes who frequently experience kidney-related complications. A second study evaluated potential interactions between Bofanglutide and metformin, one of the most widely prescribed diabetes medications globally.
Researchers reported no clinically meaningful pharmacokinetic interactions and confirmed that the combination was well tolerated. These findings support the continued development of Bofanglutide as a versatile treatment option for obesity, overweight conditions, and type 2 diabetes. The investigational therapy has already demonstrated strong weight-loss and glucose-lowering effects in previous clinical studies and is currently being evaluated across seven ongoing Phase 3 clinical programs.
Once-Weekly Insulin Programs Advance Clinical Development
Advertisement
Gan & Lee also presented new data for Insulin Ludefen (GZR4), an investigational once-weekly basal insulin designed to simplify diabetes management and improve treatment adherence. The study evaluated pharmacokinetics, safety, and tolerability in patients with mild to moderate renal impairment. Results showed that renal impairment did not significantly impact drug exposure or safety outcomes, indicating that no dose adjustment may be necessary for these patient populations. The therapy demonstrated favorable tolerability and reinforces the growing interest in once-weekly insulin formulations that reduce injection burden while maintaining effective glycemic control.
Previous Phase 3 studies have already shown that GZR4 achieved superior HbA1c reductions compared with daily insulin glargine and insulin degludec, supporting its potential to become a key competitor in the next generation of basal insulin therapies. The company believes GZR4 could help improve long-term treatment adherence and quality of life for patients requiring insulin therapy.
GZR102 Combination Therapy Strengthens Future Diabetes Treatment Strategy
Another major highlight was the presentation of GZR102, a novel once-weekly fixed-ratio combination therapy that integrates GZR4 basal insulin with Bofanglutide. Preclinical pharmacokinetic and pharmacodynamic studies demonstrated no significant drug-drug interactions between the two components, while preserving their independent pharmacological characteristics. Researchers reported promising glucose-lowering activity and meaningful weight-loss potential, supporting further advancement of the program. The combination approach is designed to address multiple disease mechanisms associated with type 2 diabetes while minimizing insulin-associated side effects such as hypoglycemia and weight gain.
Currently in Phase 2 clinical development, GZR102 represents an important component of Gan & Lee’s broader strategy to deliver more effective and convenient treatment options for metabolic diseases. As global diabetes prevalence continues to rise, the company’s expanding clinical pipeline reflects increasing industry efforts to combine innovative biologics, advanced insulin technologies, and metabolic therapies to improve patient outcomes and support the future of precision diabetes care.
Source: Gan & Lee Pharmaceuticals press release
